INTRODUCTION
Peptide hormones produced by enteroendocrine cells play central roles in the regulation of intestinal motility, nutrient digestion, and metabolism. One of these peptides, designated glucagon-like peptide-l (GLP-l), has been shown to be an important regulator of glucosedependent insulin secretion (l-3). The sequence of GLP-1 was elucidated after isolation of the complementary DNAs and genes encoding proglucagon (4-8). Despite the importance of intestinal GLP-1 for the regulation of glucose homeostasis and insulin secretion, the majority of studies of proglucagon (and GLP-1) biosynthesis have focused on analysis of proglucagon gene expression in the endocrine pancreas. These experiments used a variety of islet cell lines for analysis of the signal transduction pathways that mediate activation of proglucagon gene transcription. Islet cell lines have also been employed for gene transfer studies that have led to the identification of several c&acting DNA sequences and transcription factors important for islet cell-specific proglucagon gene transcription (9-l 1). o8684810/94$03.00/0 MdeaJlarErdoclinobgy f2pyeghtQ1994byTheEmnesoci3ty Although much has been learned about the molecular control of proglucagon biosynthesis in the islets, less is known about the control of proglucagon gene expression and GLP-1 biosynthesis in the intestine. Studies using fetal rat intestinal cell cultures demonstrated that secretion of peptides derived from the posttranslational processing of proglucagon (PGDPs) was regulated by a protein kinase-A (PKA)-dependent pathway (12). These cell cultures, although valuable for studies of peptide secretion, represent a mixture of endocrine and nonendocrine cell types (13) and, hence, are not useful for identification of the molecular factors important for proglucagon gene transcription using gene transfer studies in vitro. Furthermore, no simple methodologies for the large scale isolation of PGDP-immunoreactive intestinal L-cells have been reported.
To develop a suitable model for analysis of intestinal proglucagon gene transcription, we used an alternative strategy for the generation of an intestinal proglucagonproducing cell line. This approach involves targeting the expression of an oncogene to a specific cell population in the intestine with subsequent tumor formation, ultimately facilitating the isolation of a proglucagon-producing cell line in vitro. Although a number of peptide hormone genes (including the gene encoding proglucagon) are expressed in the gastrointestinal tract in a species-and region-specific fashion, the molecular determinants necessary for targeting transgene expression to enteroendocrine cells are not well understood. Initial studies of proglucagon gene expression in transgenie mice used a proglucagon-simian virus-40 (SV40) T-antigen transgene containing -1.3 kilobases of proglucagon gene 5'-flanking sequences (14). This transgene was expressed in the pancreas and brain, but not the intestine, of transgenic mice (14) suggesting that proglucagon gene sequences important for directing transgene expression to the intestine were different from the sequences sufficient for transgene expression in the endocrine pancreas. We subsequently constructed a larger transgene containing approximately 2.2 kilobases of proglucagon gene 5'-flanking sequences fused to the coding sequence of SV40 large T-antigen, and transgenic mice expressing this GLlJTag fusion gene consistently developed proglucagon-producing endocrine tumors of the large bowel (15).
The reproducible development of intestinal endocrine tumors in vivo provided an opportunity to isolate an intestinal cell line for studies of enteroendocrine gene expression. Intestinal tumors isolated from glucagon-SV40 T-antigen transgenic mice were passaged SC in vivo (16) and used for the derivation of cell lines in vitro. We have now propagated one such cell line, designated GLUTag, for more than 18 months in vitro. GLUTag cells synthesize and secrete high levels of the PGDPs in a regulated manner, suggesting that this cell line should be a useful model for studies of the molecular determinants of enteroendocrine gene expression.
RESULTS
GLUTag tumors from the large bowel of transgenic mice were propagated SC in vivo (16) for insulin, peptide-YY (PYY), somatostatin, and amylin were not detected by Northern analysis of total cellular GLUTag RNA (Fig. 1) . The sizes of the proglucagon mRNA transcripts in the two mouse cell lines, GLUTag and STC-1, were slightly smaller than the sizes of rat and hamster proglucagon mRNAs (Fig. 1) .
By light microscopy, the cultured cells were variable in size and shape. They had moderate amounts of pale eosinophilic cytoplasm and pleomorphic nuclei with prominent nucleoli. lmmunohistochemical staining for chromogranin-A demonstrated variable numbers of cytoplasmic granules in the majority of cells; however, some cells did not exhibit chromogranin immunopositivity (not shown). The majority of cells contained immunopositivity for GLP-1 (Fig. 2a) , glucagon, and pancreatic polypeptide (not shown), but the staining intensity was variable from cell to cell. Focal or faint staining was also detected for PYY, secretin, and somatostatin (data not shown). No positive immunostaining was detected with the CCK antisera directed against the first 39 amino acids of CCK. The cells were negative for the remainder of the antisera tested (see Materials and Methods for complete description of antisera tested).
The ultrastructural features of the cultured GLUTag cells are demonstrated in Fig. 2b . The cells had moderately well developed cytoplasmic organelles, including short profiles of rough endoplasmic reticulum, juxtanuclear Golgi complexes, numerous mitochondria, and abundant glycogen. Secretory granules were variable in number, but were well defined by a closely apposed, double limiting membrane.
Although some granules were large, measuring up to 350 nm in diameter, the majority were smaller than 150 nm, with contents of variable electron density. These features confirm endocrine differentiation and are consistent with cells of enteroendocrine lineage. The identification of proglucagon mRNA transcripts and GLP-1 immunopositivity in GLUTag cells as well as the demonstration by electron microscopy of abundant secretory granules prompted us to assess whether PGDP synthesis and secretion were regulated in GLU Tag cells. Experiments with fetal rat intestinal cell (FRIC) cultures have shown that whereas both CAMP and phorbol 12-myristate 13-acetate (PMA) stimulate the secretion of PGDPs, an increase in proglucagon mRNA transcripts was detected only with activators of the PKAdependent pathway (12). To identify the factors important for the regulation of intestinal PGDP secretion in GLUTag cells, cultures were incubated with different agents for 2 h, after which the medium was assessed by RIA for glucagon-like immunoreactivity (GLI), immunoreactive glucagon (IRG), glucagon-like peptide-l Ten micrograms of RNA from GLLlTag cells, STC-1 cells, hamster InRl-G9 islet cells, RIN1056A rat islet cells, fetal mouse large intestine (INT), and fetal mouse pancreas (PAN) were size-fractionated on an agarose gel, transferred to a nylon membrane, and hybridized with complementary DNA probes for proglucagon (G), insulin (I), CCK, PYY, somatostatin (SMS), and amylin (A). To avoid overexposure of the autoradiographs, blots were generally exposed to film for 12-36 h. With longer exposures, mRNA transcripts for proglucagon, somatostatin, PYY, and CCK could be detected in RNA from intestine (not shown). (17), had no effect on secretion of PGDPs in GLUTag cells. The phorbol ester PMA also significantly stimulated PGDP secretion (to 348 + 12% of the control value; P < 0.001). To ascertain whether these agents also stimulated the synthesis of PGDPs, the total PGDP content (the sum of 2 and 22 h media plus cellular peptides) was assessed after ' x-37 or x-36 denotes GLP-1 peptides with N-teminal sequences beginning at amino acids 1 or 7. with control medium (Con) or 10 PM forskolin plus 10 PM IBMX (FI), 5 rig/ml cholera toxin plus 10 AM IBMX (ChTI), 5 mM (BuhAMP (De), 5 mht sodium butyrate (NB), 1 PM PMA, or 1 PM TPA (n = 6 for each treatment). PGDP secretion was determined as a function of the medium content of the PGDPs after a 2-h incubation period, whereas PGDP content was calculated as the 2 and 22 h media plus the cell content of the PGDPs after a 24-h incubation.
Cl, GLI; q , IRG; n , GLP-l-(7-37); n , GLP-l-(7-36)NHz. l *, P < 0.01; ***, P < 0.001.
24-h incubation with the test agents (Fig. 3) . Activation of PKA clearly stimulated the synthesis of PGDPs in GLUTag cells (to 284 + 14%, 276 f 9%, and 269 f 21% of control values for forskolin-IBMX-, cholera toxin-IBMX-, and (BuMAMP-treated cells, respectively; P < 0.001). Small increases in PGDP synthesis were also noted with sodium butyrate and PMA treatment (135 f 8% and 170 + 9% of the control value, respectively), but not with phorbol 12,13,20-triacetate.
As RIA does not establish the molecular identity of the specific PGDPs processed from proglucagon in GLUTag cells, HPLC analysis of the cellular peptides was carried out after 24-h incubations under control conditions or after stimulation with either forskolin-IBMX or PMA. As the profiles obtained for each treatment group were identical, all data were pooled to make n = 3. The normal intestinal L-cell cleaves proglucagon to generate predominantly glicentin, oxyntomodulin, and GLP-l-(7-36)NH2 (18, 19) . The GLUTag cell line differed from the normal L-cell in that significant amounts of glucagon (57 f 2% of the total GLI) were produced in addition to glicentin, oxyntomodulin, and small amounts of the putative 9-kilodalton (kDa) peptide (17 f 2%, 20 f 2%, and 5 f 1% of the total GLI, respectively; Fig. 4) . As in the normal L-cell, however, GLP-1 -(7-36)NH2 was the predominant GLP-1 -containing peptide synthesized (78 f 7% of the total GLP-1 immunoreactivity), whereas only smaller amounts of the biologically active GLP-l-(7-37) and inactive GLP-1 -(l-36)NH2 and GLP-1 -(l-37) were produced (10 f 2%, 10 f 5%, and 2 f 1% of the total GLP-1, respectively). Finally, as similar amounts of the N-terminal PGDPs (as assessed by total GLI) and the C-terminal PGDPs (as assessed by total GLP-1) were found after HPLC analysis, these data suggest that processing of proglucagon to different molecular forms of GLP-1 in GLUTag cells is complete, with little or no high mol wt GLP-immunoreactive forms detected.
To ascertain whether forskolin induction of PGDP synthesis was mediated in part by an increase in proglucagon gene expression, GLLfTag cells were incubated with either PMA or forskolin-IBMX, and the levels of proglucagon mRNA transcripts were determined by Northern blot analysis. No increase in proglucagon mRNA transcripts was detected after exposure of the cells to PMA (data not shown). In contrast, forskolin consistently increased the levels of proglucagon mRNA transcripts, and this increase was maximal by 12 h (Fig.  5A) . Furthermore, the levels of CCK and tubulin mRNA transcripts were not significantly increased by forskolin in the same experiment. To ascertain the mechanism for the forskolin induction of proglucagon mRNA, GLU Tag cells were incubated with forskolin-IBMX in the presence of the transcriptional inhibitor actinomycinD. A small decrease in the levels of proglucagon mRNA transcripts was detected after a 12-h incubation with actinomycin-D alone, consistent with the known halflife (20) of proglucagon mRNA transcripts (Fig. 58) . Actinomycin-D almost completely inhibited the forskolin induction of proglucagon gene expression, suggesting that the increase in proglucagon mRNA transcripts was primarily attributable to an increase in proglucagon gene transcription. No induction of actin mRNA transcripts by forskolin was detected in the same experiment (Fig.  5B) . To provide more direct evidence for the effect of forskolin on proglucagon gene transcription, nuclear run-on experiments were carried out after treatment of GLUTag cells with vehicle alone or forskolin-IBMX. The results of this experiment (Fig. 6) clearly demonstrated that forskolin increased the transcription rate of the proglucagon gene (6-fold by densitometry) in GLLfTag cells, whereas no comparable induction of the transcrip plex, exhibiting species-and region-specific differences in distribution as well as in hormone expression throughout the gastrointestinal tract (22). Immunocytochemical studies of enteroendocrine cell differentiation in normal mouse intestine have demonstrated several populations of endocrine cells that contain one or more peptide hormones (22). Enteroglucagon and PYY as well as neurotensin have been shown to be colocalized within the same enteroendocrine cell. The hormone most commonly colocalized with GLP-1 in mouse large intestine is CCK, with 48% of GLP-l-immunoreactive cells containing both immunoreactive GLP-1 and CCK (23). These observations are consistent with our observations that GLUTag cells express both the proglucagon and CCK genes, suggesting that the hormonal phenotype of the GLUTag cell line may be representative of a distinct lineage of mouse enteroendocrine cells.
The majority of studies to date analyzing the control of proglucagon gene transcription have used islet cell lines derived from tumors arising from the endocrine pancreas (10, 20, 24, 25). These experiments have defined the signal transduction pathways and &-acting DNA sequences important for control of pancreatic proglucagon gene transcription. In contrast, very little is known about the regulation of proglucagon biosynthesis in the intestine, and several lines of evidence suggest that important differences may exist in the control of islet vs. intestinal proglucagon gene expression. Studies using the rat islet cell RIN1056A have suggested that pancreatic proglucagon gene transcription may be regulated by a protein kinaseC-dependent pathway (20) whereas PMA had no effect on proglucagon mRNA transcripts in GLLfTag cells or in studies using FRIC cultures (12). Furthermore, experiments using transgenic mice to define tissue-specific domains important for proglucagon gene transcription have suggested that the proglucagon gene sequences required for targeting transgene expression to the pancreas and nervous system are not sufficient for expression in the intestine (14, 15) . The isolation of a novel proglucagonproducing enteroendocrine cell line represents an important advance for studies of both the regulation and tissue-specific determinants of intestinal proglucagon gene expression.
The observation that proglucagon gene transcription in GLLfTag cells is regulated by a PKA-dependent pathway represents the first direct demonstration that CAMP activates proglucagon gene expression at the level of gene transcription. Although proglucagon mRNA transcripts are regulated by a PKAdependent pathway in primary cultures of rat islet and intestinal cells (12, 26) studies using immortalized islet cell lines have not demonstrated direct CAMP-dependent induction of proglucagon gene transcription (10, 24) . Previous studies of proglucagon gene expression using primary cell cultures have shown that proglucagon mRNA was regulated by activators of PKA, but the precise mechanism for this effect (either a prolongation of the mRNA tjj2 or transcriptional induction) had not been ascertained. Furthermore, islet cell lines that express proglucagon exhibit a defect in CAMP-mediated gene expression and have not proven useful for analysis of the CAMP-dependent transcriptional control of proglucagon gene expression (24, 27) . More recent studies have circumvented this limitation by transfecting islet cell lines with the catalytic subunit of PKA. The results of these experiments have mapped a putative proglucagon gene PKA-response element to a specific CAMP response element sequence in the 5'-flanking region of the rat proglucagon gene from -292 to -298 that binds CAMP response element-binding protein and mediates activation of repotter gene expression by a cotransfected catalytic subunit of PKA (26, 28, 29) .
The posttranslational processing of proglucagon in GLUTag cells exhibited both similarities and differences compared with the nonimmortalized intestinal L-cell. Consistent with normal intestine, GLP-l-(7-36)Nfi, was the predominant GLP-l-containing peptide in cell extracts. In contrast, the predominant molecular species derived from the N-terminal end of proglucagon was glucagon, whereas little or no glucagon is usually found in normal L-cells (19, 30) . This aberrant pattern of processing was initially observed in the original intestinal tumors in transgenic mice, which contained approximately equivalent amounts of glicentin, oxyntomodulin, and glucagon (15).
The posttranslational processing of proglucagon has also been previously analyzed in a number of different tumor-derived islet and intestinal cell lines. Although mouse (Y-TC-1 islet cells process proglucagon in a pancreatic-specific manner (25) an aberrant pattern of proglucagon processing, inconsistent with the expected cellular phenotype, was detected in studies of InRl-G9, RIN1056A, and STC-1 cells (10, 24, 31) . Aberrant processing in these cell lines was also reflected by the detection of a spectrum of PGDPs that overlapped the expected pancreatic-and intestinal-specific patterns of proglucagon processing. Furthermore, propagation of GLUTag tumors SC in vivo is associated with a switch in the pattern of proglucagon processing away from that exhibited by the normal intestinal L-cell (16). The mechanism(s) underlying these cellular switches in the phenotype of proglucagon processing is not known, but is probably attributable to differential expression of the prohormone convertases, enzymes that may be responsible for the tissue-specific patterns of proglucagon processing (32).
Curiously, although Northern blot analysis detected CCK mRNA transcripts in GLUTag RNA, no CCKimmunopositive GLUTag cells were observed using antisera directed against CCK-(l-39). In contrast, the identical antisera consistently detected CCK-immunopositive cells in sections from control mouse intestine. These observations suggest that either the CCK mRNA is not translated in GLUTag cells or, alternatively, the CCK prohormone is aberrantly processed or degraded, precluding recognition by the antisera used here. Evidence for incomplete processing of CCK in vivo has been obtained from studies of CCK expression in the pituitary (33). Furthermore, although CCK mRNA is readily detectable in porcine cerebellum, no immunoreactive CCK peptides could be detected in the same tissue using a panel of CCK-specific antisera (34). Taken together, the detection of CCK mRNA, but not immunoreactive CCK, in GLUTag cells suggests that this cell line may also be useful for studies of the control of CCK translation in vitro.
Previous transgenic experiments that involved mating two lines of transgenic mice (rat insulin promoter-SV40 Tag x rat insulin promoter-polyoma Tag) resulted in the establishment of several lines of double transgenits, one line of which developed endocrine tumors of the small intestine, presumably due to an integration effect (35) . Although the precise cellular and embryological derivation of these rapidly metastasizing tumors could not be defined, a secretin tumor cell line (designated STC-1) established from these tumors produced large amounts of secretin as well as neurotensin, and pancreatic polypeptide in vitro (36 
RNA Isolation and Analysis
Total cellular RNA was isolated using the acid-ethanol precip itation method, as previously described (37). For Not-them blotting, RNA was size-fractionated on a formaldehyde-agarose gel, and the gel was stained with ethidium bromide to assess the loading and integrity of the RNA. The RNA was subsequently transferred to a nylon membrane and fixed with LJV fight. and hybridization and washing were carried out as previously described (12). Nuclear run-on assays were carried out as described previously (20, 38 In experiments analyzing PGDP secretion and content, data for each of the four RlAs were analyzed separately and then combined for analysis; the trends were found to be identical, and therefore, only the results of the combined analyses are shown.
